Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

You may be eligible if

• Patients enrolled in must meet ≥ 1 of the following criteria:
• * History of unilateral or bilateral atypical ductal hyperplasia with or without family history
• * History of atypical lobular hyperplasia or lobular carcinoma in situ with or without family history
• * History of ductal carcinoma in situ
• * Prior stage I breast cancer allowed provided it was adequately treated and therapy was completed ≥ 1 year ago
• * Lifetime risk for developing breast cancer \> 20% (based on Gail or Claus model)
• * No abnormal mammogram requiring short-term follow-up within the past 6 months
• * No severe atypia or carcinoma cells on RPRNA
• PATIENT CHARACTERISTICS:
• Premenopausal
• ECOG performance status 0-1
• Patients enrolled must meet the following criteria:
• * No peri- or postmenopausal status as determined by estradiol levels \< 20 ng/dL and FSH levels \> 45 ng/dL
• * No thrombocytopenia (defined as platelet count \< 50,000/mm\^3)
• * Creatinine ≤ 1.5 mg/dL
• * Not pregnant or nursing
• * Fertile patients must use effective contraception consistently
• * No other prior malignancy allowed except for the following:
• * Basal cell or squamous cell carcinoma
• * In situ cervical cancer
• * No history of any of the following conditions within the past 5 years:
• * Crohn disease
• * Ulcerative colitis
• * Inflammatory bowel disease
• * Irritable bowel syndrome
• * Celiac sprue
• * Malabsorption syndrome
• * Diverticulitis
• * Diverticulosis
• * No allergy to flaxseed, other seeds or nuts, or wheat
• PRIOR CONCURRENT THERAPY:
• Patients enrolled in part 1 must meet the following criteria:
• * No prior breast implants or tram-flap reconstruction
• * Breast reduction allowed
• * No prior neoadjuvant chemotherapy or other chemotherapy within the past year
• * No prior neoadjuvant hormonal therapy
• * No prior whole radiation to the contralateral breast undergoing random periareolar fine needle aspiration (RPFNA)
• * No concurrent coumadin or other chronic anticoagulants (even if they are held for surgery)
• Patients enrolled in part 2 must meet the following criteria:
• * More than 1 year since prior chemotherapy and adjuvant hormonal therapy for breast cancer
• * No concurrent chemotherapy for breast cancer
• * At least 1 month since prior and no concurrent treatment with corticosteroid
• * At least 2 weeks since prior and no concurrent use of antibiotics
• * At least 2 weeks
• * No history of chest wall irradiation
• * No presence of breast implants
• * No prior or concurrent tamoxifen within the past 90 days
• * No chronic/concurrent medications that inhibit platelet function, including any of the following:
• * Aspirin
• * Non-steroidal anti-inflammatory drugs (i.e., Aleve®, Motrin®, ibuprofen)
• * Coumadin
• * Heparin
• * Low molecular weight heparin
• * Anti-platelet agents
• * No prior short-term use of platelet inhibitors ≥ 7 days prior to RPFNA
• * No concurrent ingestion of the following:
• * Pumpkin seeds
• * Sesame seeds
• * Fish oil supplements
• * At least 30 days since prior and no concurrent flaxseed supplements, fish oil, or flaxseed oil
• * No concurrent treatment for another malignancy